Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)

Tr1X, Inc.5 sites in 1 country36 target enrollmentApril 8, 2024

ConditionsHematologic Malignancy GvHD GVHD,Acute GVHD, Chronic Hematopoietic Stem Cell Transplant Acute Lymphoblastic Leukemia, Adult B-Cell Acute Lymphoblastic Leukemia, Adult T-Cell Acute Myeloid Leukemia in Remission Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia, in Remission Cancer Remission

InterventionsTRX103

DrugsTRX103

Overview

Phase: Phase 1
Intervention: TRX103
Conditions: Hematologic Malignancy
Sponsor: Tr1X, Inc.
Enrollment: 36
Locations: 5
Primary Endpoint: Safety and tolerability of TRX103 cell infusion through incidence of Adverse events.
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.

Registry

clinicaltrials.gov

Start Date

April 8, 2024

End Date

April 15, 2027

Last Updated

last year

Study Type

Interventional

Study Design

Sequential

Sex

All

Investigators

Sponsor

Tr1X, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects with one of the following hematologic malignancies: Acute Lymphoblastic Leukemia (B- or T-ALL), Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), or Chronic myelomonocytic leukemia (CMML)
•Males and Females Age ≥ 18 years.
•Weight of ≥ 35 Kg.
•Karnofsky performance status ≥ 70 %.
•Available mismatched related (haploidentical) or unrelated donors for peripheral blood stem cell (PBSC) donation.
•Subjects must otherwise fulfill institutional criteria for eligibility to undergo allogeneic stem cell transplantation.
•Absence of uncontrolled bacterial, viral or fungal infection at time of enrollment.
•Have adequate organ function.
•Subjects \> 65-year-old receiving MAC conditioning will only be eligible if they have a HSCT-comorbidity index score \<
•Subjects must be able to understand and sign informed consent and be willing and able to complete all specified procedures and visits.

Exclusion Criteria

•Prior allogeneic bone marrow, peripheral blood, or cord blood HSCT.
•Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction.
•HIV positive.
•Positive hepatitis-B surface antigen. Subject may be included if they are HBV PCR negative.
•Positive hepatitis-C antibody with positive Recombinant Immunoblot Assay (RIBA) or PCR unless the subject has received curative anti-viral treatment and confirmed negative viral load by PCR.
•Received another investigational agent for treatment of disease understudy within 28 days (or 5 half-lives, whichever is shorter) of conditioning and/or have not recovered from treatment related toxicities.
•Subjects with a previous history of Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS) who are not good candidates for treatment with sirolimus.
•Subjects that are pregnant, breast feeding or aim to become pregnant during the study period. (Subjects must agree to use a highly effective method of contraception).
•Any serious illness, uncontrolled inter-current illness, psychiatric illness, active or uncontrolled infection, or other medical condition or history, including laboratory results.

Arms & Interventions

TRX-103

TRX-103 will be infused on time post hematopoietic stem cell transplant (HSCT).

Intervention: TRX103

Outcomes

Primary Outcomes

Safety and tolerability of TRX103 cell infusion through incidence of Adverse events.

Time Frame: Up to a year

Safety of TRX103 determined by stem cell engraftment and donor chimerism after HSCT measured by absolute neutrophil counts and percent donor chimerism.

Time Frame: Up to day 42

Safety of TRX103 determined by negative Replication Competent Lentivirus (RCL).

Time Frame: At 3-month, 6-month, and 1-year.